H eart failure (HF) is a state of chronic inflammation, characterized by heightened levels of circulating and myocardial proinflammatory cytokines that promote pathological left ventricular (LV) remodeling. 1, 2 Although preclinical and early human studies suggested a therapeutic role for cytokine antagonism in HF, 1 large-scale clinical trials of antibody-based cytokine neutralization in HF failed to show benefit. [3] [4] [5] The failure of immunomodulation trials suggests an incomplete understanding of the nature of inflammation in HF. Specifically, as plasma cytokine levels are in large part determined by the combined influences of innate and adaptive immune system activation, they may be less-sensitive indexes of underlying disease pathogenesis than the direct effects (both locally and systemically) of specific immune cell populations on the heart. In this regard, we have recently demonstrated robust expansion of monocytes/macrophages and dendritic cells (DCs) in chronic ischemic HF in the context of a proinflammatory cardiosplenic axis, with activated splenocytes homing to failing heart to induce tissue injury. 6 These observations further suggested that directly targeting specific leukocyte populations might represent a more fruitful approach to immunomodulation in HF. T cells in Heart Failure heart and play a crucial role in promoting cardiac fibrosis, hypertrophy, and remodeling. 12, 13 In human HF secondary to either ischemic or nonischemic causes, a low circulating total lymphocyte count is predictive of poor outcomes and prognosis; 14 however, the impact of specific lymphocyte subpopulations, and their relationship to HF disease stage, are poorly understood. CD4 + T cells are composed of a heterogeneous family of adaptive immune cells with specialized functions. 15, 16 These include proinflammatory T-helper (Th)1 cells that produce interferon-γ (IFN)-γ and interleukin (IL)-2, 17 anti-inflammatory Th2 cells that produce IL-4, IL-5, and IL-13, 18 proinflammatory Th17 cells that secrete IL-17, 19 and immunomodulatory regulatory T cells (Tregs) that globally suppress the activation of immune responses. 20 Given that ischemic HF is a chronic inflammatory state, it follows that alterations in the activation and spatiotemporal distribution of T-cell subsets during the development of HF may have considerable impact on the progression of pathological LV remodeling. Accordingly, we characterized temporal changes in circulating T-lymphocyte profiles during the development of ischemic HF, the status of various CD4
+ T-cell subsets in the heart, mediastinal lymph nodes (LNs), and spleen in chronic HF 8 weeks after MI, and, using a combination of antibody-mediated depletion and cardiac and splenic T-cell adoptive transfer, delineated the pathophysiological role of T cells in HF progression. Our results indicate that T cells are globally expanded and activated in chronic ischemic HF and are indispensable for the progression of pathological LV remodeling.
Methods
All animal studies were approved by University of Alabama at Birmingham Institutional Animal Care and Use Committee and were compliant with the NIH Guide for the care and Use of Laboratory Animals (DHHS publication No. 85-23, revised 1996) . A total of 138 mice were used for all the studies.
Mouse Model and Surgical Protocol
Male, 8-to 10-week-old C57BL/6 mice (Jackson Laboratories, stock no. 000664) underwent left thoracotomy and either sham surgery (n=28) or left coronary artery ligation (n=80) to induce MI and ischemic HF, as previously described. 6, [21] [22] [23] [24] Peripheral blood was collected serially (1, 2, 4, 6 and 8 weeks post MI) from the facial vein, and all the mice were euthanized at 8 weeks post MI. Heart, spleen, and heart-draining mediastinal LNs were collected at the time of euthanasia, and mononuclear cells were isolated either for T-cell analysis by flow cytometry or for adoptive transfer studies (see below).
Echocardiography
Murine echocardiography was performed under 1% to 2% isoflurane anesthesia using a VisualSonics Vevo 770 High-Resolution System, a heated, bench-mounted adjustable rail system (Vevo Imaging Station) and RMV707B scanhead as previously described. 
Immune Cell Isolation
Immune cell isolation from peripheral blood, myocardium, spleen, and LNs was performed as described previously. 6 Blood (≈100 μL) was collected into EDTA containing tubes and lysed with RBC lysis buffer (600 μL) for 10 minutes (eBioscience). After lysis was complete, excess buffer was neutralized by adding 10 mL of cold phosphate-buffered saline and centrifuged at 380g. The cell pellet was reconstituted in 100 μL of staining buffer and labeled for flow cytometry as described below. The heart underwent collagenase digestion followed by filtration through 40-µm filters to remove extracellular connective tissue debris before centrifugation and reconstitution. Inflammatory cells from lymphoid tissue (spleen and LNs) were extracted as detailed previously. 6 
Flow Cytometry
Cell pellets were resuspended in staining buffer and incubated with a cocktail of antimouse CD3-FITC/PE (BD Biosciences), CD4-Qdot650NC/PECY7/eVolve 605/PerCP-Cy5.5 (eBioscience), CD8-Qdot605NC/eVolve 655 (eBioscience), and NK1.1-PE/AF700 (eBioscience) (and in separate experiments CD44-PE from BD Biosciences and CD62L eVolve 605 and CD69-AF700 from eBioscience) fluorochrome-conjugated antibodies for 1 hour. After washing with phosphate-buffered saline, the cells were fixed using 1% paraformaldehyde, permeabilized for 30 minutes with 0.5% v/v tween-20 and stained with fluorochrome-conjugated antibodies (eBioscience) targeting the intracellular cytokines IFN-γ, IL-4, and IL-17, and the transcription factor Foxp3. In some experiments, cells were fixed before staining with antibodies for cell surface markers. After 1 hour, the cells were washed with phosphate-buffered saline and data were acquired by BD FACSdiva LSR-II Flow cytometer (BD Biosciences). FlowJo software version 10.0.6 was used for data analysis. From a separate group of mice, 100 µL of blood, 15 to 20 mg of spleen, and 1 mediastinal LN were analyzed for cell counts, whereas whole tissue was digested for absolute counts of cardiac T cells. AccuCount beads were used to adjust for differences in events recorded by the flow cytometer. The total live cell side scatter/forward scatter (SSC/ FSC) gate was used to normalize cell populations in the spleen, mediastinal LNs, and heart, whereas the total lymphocyte-monocyte gate was used in peripheral blood. The pan T-cell marker CD3 was used to identify all lymphocytes. Helper and cytotoxic T cells were defined as CD3 
Measurement of Circulating Cytokines
Blood was collected from the facial vein, clotted and centrifuged at 4000g (10 minutes at 4°C), and serum was separated and stored at −80°C for analysis. Simultaneous analysis of circulating T-lymphocyte-related cytokines (IFN-γ, tumor necrosis factor-α, IL-17, IL-6, IL-10 and IL-4) was performed using the mouse Th1/Th2/ Th17 Cytometric Bead Array (CBA) kit (BD Biosciences) following the manufacturer's protocol. Briefly, 50 μL of serum or standard was incubated with 50 μL of bead mixture and PE-conjugated detection antibody at room temperature. After 2 hours, excess PE-conjugated reagent was removed by washing with 1 mL of wash buffer, and samples were subsequently analyzed on a BD LSRII flow cytometer. FCAP Array software was used to measure mean fluorescence intensity of each cytokine, and serum concentrations were calculated from standard curves prepared simultaneously.
Cardiac and Splenic Gene Expression by Quantitative Real-Time PCR
RNA extraction from LV tissue (encompassing remote and border zone myocardium), cDNA synthesis, and quantitative real-time PCR were performed as previously described. [21] [22] [23] Methodology for the determination of splenocyte gene expression has been previously detailed. 6 Briefly, splenic mononuclear cells were isolated by layering on a Ficoll-Paque gradient and incubated in serum-free Dulbecco's Modified Eagle Medium overnight. Adherent cells were collected and stored at −80°C in TRIzol reagent (Invitrogen) for subsequent RNA extraction and measurement of mRNA transcript levels. Gene expression was determined for IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-18, IL-33, IL-12Rβ2, IFN-γ, transforming growth factor-β, and C-C chemokine receptor type 5. The forward and reverse primer pairs used to determine gene transcript levels are provided in Table I in the Data Supplement. Gene expression was normalized to β-actin for LV tissue and 18s rRNA expression for splenocytes using the ΔΔC T comparative method and expressed as fold-changes. Th1/proinflammatory mediators considered were IFN-γ (Th1 T-cell-specific cytokine), 17 IL-12Rβ2, and C-C chemokine receptor type 5 (receptors induced during Th1 polarization), 28 IL-18 (promotes Th1 polarization), 29 IL-17 (produced by Th17 cells 19 ), and IL-2 (released by T cells 30 ). For anti-inflammatory markers, we measured IL-4, IL-5, and IL-13 (cytokines released by Th-2 cells 18 ), transforming growth factor-β and IL-10 (anti-inflammatory cytokines released by Tregs and Th-2 T cells 31 ), and IL-33 (inducer of Th-2 related cytokines 32 ).
Histological Analysis
Formalin-fixed, paraffin-embedded hearts from sham and HF mice were sectioned at 5-μm thickness, deparaffinized, and rehydrated. Histological staining was performed as previously described. 6, 21, 23 Masson's trichrome was used to evaluate tissue fibrosis and Alexa Fluor 488-conjugated wheat germ agglutinin (Invitrogen) to assess myocyte area, as quantified from 5 to 6 high-power fields per section in noninfarcted myocardium using Metamorph software version 6.3r5 (Molecular Devices).
To evaluate for tissue abundance of CD4 + and CD8 + T cells, heart sections were embedded in OCT compound (Tissue-Tek OCT), and then kept at −80°C until sectioning. Sections (7 μm thickness) were fixed with 4% paraformaldehyde in phosphate-buffered saline, and labeled with either rat antimouse CD4 (Clone GK1.5; eBiosciences) or CD8 antibody (Clone 4SM15; eBiosciences). Goat antirat antibody conjugated with Alex Fluor 555 and 488 (Life Technologies) were used as secondary antibodies for CD4 and CD8, respectively, and fluoroshield-containing DAPI (Sigma-Aldrich) was used as the mounting medium. CD4 + or CD8 + cells were quantified using confocal microscopy from 5 to 6 sections and 3 to 4 mice from each group. All measurements were conducted in a blinded manner. Confocal microscopy was performed on an LSM710 microscope (Zeiss).
Antibody-Mediated In Vivo CD4 + T-Cell Ablation
Four weeks after coronary ligation, C57BL/6 mice with comparable degrees of post-MI LV dilatation and dysfunction (as assessed by echocardiography) were randomized to receive either purified anti-CD4 antibody (100 µg/mouse IP, GK 1.5 clone, eBioscience) for a total of two doses administered 10 d apart (n=10) or IgG isotype control antibody at the same doses (n=6). Echocardiography and blood collection were performed before and 4 weeks after the initiation of treatment (ie, 4 and 8 weeks post MI) for serial evaluation of LV structure/function and circulating T cells. The mice were then euthanized 8 weeks post MI, with subsequent gravimetric and tissue analyses as described above.
Adoptive Transfer Studies
CD3 + T cells from the heart and CD4 + T cells from the spleen were harvested from naive control (n=6) and HF mice (n=6; 8 weeks post MI) and used for adoptive transfer into naive recipient mice as described below.
Splenic CD4 + T Cells
Mononuclear splenocytes from naive control and HF mice were isolated as described previously. 6 Splenic CD4 + T cells were separated and collected using the mouse CD4 + T-cell isolation kit (Miltenyi) following the manufacturer's protocol. Cell recovery was 12×10 6 cells per spleen, with 85% to 90% purity of the CD4 + T-cell population by flow cytometry and 90% to 95% cell viability by trypan blue exclusion.
Cardiac CD3 + T Cells
Naive control and HF hearts were minced and digested with collagenase, and cardiac mononuclear cells were isolated as described previously. 6 Cells were labeled with CD3-FITC (BD Biosciences) for 30 minutes at 4°C. Viable CD3 + T cells were identified by exclusion of the fluorochrome 7-amino actinomycin D (7-AAD) and then sorted by flow cytometry.
Because of the labor-intensive experimental setup, tissues from 3 animals were processed per day. Cells isolated from either 3 HF or control mice each day were pooled, divided into equal aliquots, and adoptively transferred intravenously to syngeneic naive C57BL/6 recipient mice. The interday variability in the number of transferred splenic CD4 + T cells was negligible, ranging from 11 to 13×10 6 cells. However, the number of cardiac CD3 + T cells adoptively transferred to recipients varied on different days because of inconstant yield from control and failing hearts. The first group (n=3) of naive recipients administered failing cardiac T cells were given ≈7300 CD3 + cells intravenously, whereas the second group (n=3) received ≈48 100. Naive recipients administered control cardiac T cells were given between 15 400 and 18 200 CD3 + cells (n=6 total). Recipient mice were followed by serial echocardiography performed at baseline (day 0) and 4 and 8 weeks after cell transfer. After 8 weeks, mice were euthanized and tissues harvested for gravimetric and histological analysis.
Statistical Analysis
All quantitative analyses are mean±SD. For statistical analyses, the variance of data sets was first assessed using the F-statistic, and the D'Agostino-Pearson test was used to assess normality. Statistical comparisons between HF and sham/control groups were then performed using the unpaired Student's t test with equal or unequal variance, for normally distributed data. For non-normally distributed data (observed with quantitative data of absolute T-cell number in the myocardium), logarithmic transformation was first performed to satisfy the assumption of normality, followed by analysis using the unpaired Student's t test with equal or unequal variance. Repeated-measures ANOVA and Bonferroni post-test were used to analyze the adoptive transfer studies. GraphPad Prism version 7.0a was used for all analyses. A P value of <0.05 was considered significant.
Results

Profound Structural LV Remodeling in Chronic Ischemic HF
Cardiac structural and functional parameters for control and HF mice 8 weeks after sham surgery or coronary ligation are shown in Figure I in the Data Supplement. Representative gross heart specimens and M-mode echocardiograms of sham and failing hearts demonstrated cardiac enlargement, LV dilatation, and LV systolic dysfunction in HF mice. As seen in the group data ( Figure IA in the Data Supplement), HF mice exhibited markedly increased LV end-diastolic and endsystolic volume, severely reduced LV ejection fraction, and significantly increased heart and wet lung weights consistent with cardiac hypertrophy and pulmonary congestion ( Figure  IB in the Data Supplement). Increased spleen size and weight, along with increased total counts of splenic CD45 + leukocytes and CD3 + T cells, were also evident in HF mice (Figure IC in the Data Supplement), consistent with splenic remodeling occurring in HF, as demonstrated in our earlier study. 6 Hence, there was substantial pathological LV remodeling 8 weeks post MI and evidence of chronic HF. 
CD4 + T Lymphocytes Are Globally and Progressively Expanded in HF
cells in Heart Failure
However, in ligated mice, blood CD4 + T-cell frequency was significantly higher than sham at nearly all time points after MI (only the 2 weeks post MI interval did not reach significance, P=0.064), and measured absolute circulating CD4 + cell count was elevated at both 1 and 8 weeks after MI (Figure 1B) . Similarly, the frequency of CD8 + T cells was significantly increased over sham mice both early (1 week) post-MI and in established HF (≥4 weeks after MI), as was the absolute circulating CD8 + T-cell count 8 weeks after MI ( Figure  IIA in Figure 1C) . Furthermore, absolute Th1, Th2, and Th17 cell counts were all significantly increased in HF mice when compared with sham at 8 weeks post MI ( Figure 1D ). Th1 and Th2 cell counts were also elevated early (1 week) post-MI. In contrast, the profile of circulating Tregs, an immunomodulatory CD4 + T-cell subset, was biphasic in HF mice, with no change in either frequency or absolute counts early (1 week) post-MI, and then augmented levels onward from 2 weeks post MI, including increased total counts at 8 weeks when compared with sham mice. Consistent with the cell data, mice with HF (8 weeks post MI) exhibited the elevated serum levels of cytokines that induce either Th1 cells (IFN-γ and tumor necrosis factor-α), Th2 cells (IL-6 and IL-10) or Tregs (IL-10) 34,35 when compared with sham, but without observed differences in serum IL-17 and IL-4 ( Figure 1E ). + T cells were readily observed in failing hearts, at nearly 3-to 5-fold higher levels than in sham hearts (P=0.018 and 0.022, respectively). Cardiac T-cell subpopulations were quantified by flow cytometry. As depicted in Figure 3A , >95% of cardiac mononuclear cells were viable and excluded the membrane impermeant fluorochrome 7-AAD. Scatter plots for CD4-, CD8-, and Foxp3-stained CD3 + T cells indicated significantly augmented populations of CD4 + helper, CD8 + cytotoxic, and Foxp3 + regulatory T cells in failing hearts ( Figure 3B ; Figure IIC in the Data Supplement). Of the Th subsets, cardiac Th1, Th2, and Th17 populations were all robustly increased in HF when compared with sham ( Figure 3C ). The cardiac Th1/Th2 ratio was decreased in HF, indicating a Th2 predominant milieu in failing myocardium and was accompanied by an augmented Th17/Treg ratio ( Figure 3D ). This cell profile was accompanied by diffuse mRNA upregulation of multiple Th2 (and Treg) polarizing inflammatory mediators in border and remote zone failing myocardium (IL-4, IL-13, IL-5, IL-33, transforming growth factor-β, and IL-10) but only select overexpression of Th1 and Th17 polarizing mediators when compared with sham (IL-18 and IL-17; no difference in IFN-γ, IL12Rβ2, C-C chemokine receptor type 5, and IL-2; Figure 3E ).
CD4 + T Lymphocytes Are Augmented in the Failing Heart
CD4 + T Lymphocytes Are Broadly Activated in the HF Spleen and Mediastinal LNs
In HF mice, the hypertrophied spleen exhibited expansion of both CD4 + and CD8 + T cells when compared with sham (Figures 4A ; Figure IID + T cells, defined by high CD44 expression, 25 were also expanded significantly in HF mice ( Figure 4D ). This expansion was composed of increased levels of both CD44 hi CD69
+ activated effector T cells and CD44 hi CD69
-total memory CD4 + T cells 27 (Figure 4E ). Splenic central memory T cells 27 as identified by CD44 hi CD62L
hi expression were also significantly elevated in HF mice when compared with sham ( Figure 4F ). Like the spleen, mediastinal LNs in HF mice were enlarged when compared with sham mice, with similar increases in cell frequencies and counts of CD4 + T cells and the Th1, Th2, Th17, and Treg subsets, consistent with immune activation ( Figure III were randomly assigned to receive either anti-CD4 antibody or isotype IgG control antibody, and LV remodeling and T-cell subsets were assessed at 8 weeks ( Figure 5A ). Anti-CD4 treatment selectively depleted CD4 + T cells in the blood, spleen, mediastinal LNs, and heart, without affecting circulating CD8 + T cells ( Figure 5B) . Moreover, CD4
+ T-cell depletion reduced LV and splenic remodeling, as evidenced by lower normalized heart, LV, and spleen weight when compared with control antibody ( Figure 5C ). In addition, echocardiography revealed progressive LV chamber dilatation in HF mice treated with control antibody that was prevented by the administration of anti-CD4 antibody ( Figure 5D ), without significant effects on LV ejection fraction. Hence, CD4 + T cells are necessary for the progression of pathological structural remodeling. + T cells were also tested as a T-cell population presumably enriched for activation against cardiac antigens. Recipient mice were followed for 8 weeks, with serial echocardiographic assessment of LV function every 4 weeks. As illustrated in Figure 6B , transfer of HF-activated splenic CD4 + T cells induced significant LV systolic dysfunction (increased end-systolic volume and reduced ejection fraction) and LV hypertrophy (increased LV wall thickness) during this time, but without chamber dilatation (no change in end-diastolic volume), when compared with mice that received control splenic CD4 + T cells. Gravimetric analysis 8 weeks after cell transfer revealed a significant increase in normalized heart weight (Figure 6C) , and histological analysis indicated a mild but significant augmentation of interstitial fibrosis and robust myocyte hypertrophy ( Figure 6D 
CD4 + and CD3 + T Cells Are Sufficient to Induce Cardiac Remodeling
Discussion
There are several key and novel findings in this study. First, in chronic ischemic cardiomyopathy, there is systemic expansion of CD4 + and CD8 + T cells and CD4 + Th1, Th2, Th17, and Treg subsets, which encompasses the failing heart, circulation, and lymphoid organs. Second, there is temporal divergence in the behavior of Th subsets during the progression of ischemic HF and organ-localized differences in Th-cell distribution in + and cardiac CD3 + T cells in HF are biologically active and primed for myocardial injury, and sufficient for the production of pathological remodeling. Taken together, we conclude that systemic CD4 + T-cell activation, presumably directed toward cardiac antigens, plays an indispensable role in the progression of adverse cardiac remodeling in chronic ischemic HF.
Chronic Ischemic HF Is a Systemic CD4 + TCell-Activated State
Multiple immune cell types infiltrate the acutely infarcted heart in a phasic manner during early post-MI remodeling. [36] [37] [38] [39] [40] Following an early wave of neutrophils, infiltrating proinflammatory (Ly-6C hi ) monocytes promote tissue digestion early (1-4 days) after MI and subsequently differentiate into reparative (Ly-6C low ) macrophages that resolve inflammation and promote fibrosis over several days. In concert with DCs, 41 CD4 + T cells, 8 including Foxp3 + Tregs, 9 infiltrate the heart and promote wound healing after MI by favorably influencing monocyte/macrophage trafficking and differentiation and by facilitating collagen matrix formation and angiogenesis. Indeed, effective myocardial repair and remodeling after ischemic injury are critically linked to tissue-level responses mediated by both innate and adaptive immune cells. 39 Importantly, early post-MI remodeling is ultimately marked by inflammation resolution and quiescence; consequently, the aforementioned studies provide little insight as to how T cells might affect ischemic cardiomyopathy and HF, a disease state with a substantially different inflammatory profile.
We recently demonstrated that ischemic cardiomyopathy (well after completion of early post-MI remodeling) is characterized by sustained expansion of proinflammatory 
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macrophages and DCs in the heart, together with splenic remodeling consistent with heightened antigen processing. 6 Moreover, activated mononuclear splenocytes trafficked to the failing heart to promote apoptosis, fibrosis, and dysfunction, suggesting that adverse LV remodeling was, in part, immunemediated. Although T cells were not rigorously examined, given that a primary function of DCs is the presentation of antigens to T cells 7 robust DC expansion intimated that T-cell activation, and perhaps T-cell-mediated tissue injury in the heart, are also central to pathological remodeling. In this regard, recent studies of murine nonischemic (pressure overload-induced) HF have indicated that heart infiltrating, activated CD3 + CD4
+ T cells impart detrimental effects on LV remodeling. 12, 13 However, the role of CD4 + T cells, and the behavior of various CD4 + T-cell subsets, in chronic ischemic HF, in which the heart exhibits much more robust initial cell death, has heretofore been poorly understood.
Our data establish (to our knowledge for the first time) that in chronic ischemic HF, there is robust T-cell expansion of both CD4 + and CD8 + T cells, and CD4 + Th1, Th2, Th17, and Tregs, both within the failing myocardium and globally in the lymphoid organs and circulation. Interestingly, although all CD4 + T-cell subsets were expanded in the failing heart, the Th1/Th2 ratio was significantly diminished (classically antiinflammatory), whereas the Th17/Treg ratio was increased (classically proinflammatory). Moreover, HF was characterized by robust proinflammatory gene expression in spleen, and augmented levels of splenic CD4 + CD44
hi CD69 + antigenexposed effector T cells, 25, 27 CD4 + CD44 hi CD69 − total memory T cells 27 and CD4 + CD44 hi CD62L hi central memory T cells, consistent with T-cell activation presumably in response to self-antigens during MI or post-MI remodeling, with potential for reactivation of heart-directed adaptive immunity on repeated exposures. These findings indicate that HF is not easily categorized as a "Th1" or "Th2" inflammatory state, but rather that T-cell alterations are spatiotemporally complex in the context of disease. This notion is in line with the understanding that CD4 + T cells are composed of a heterogeneous family of pro-and anti-inflammatory T cells with diversely varying properties. 15 In the failing heart, the reduced Th1/ Th2 cell ratio suggests that expanded cardiac Th2 cells may induce local damage by secreting Th2 cytokines, which are known fibrogenic factors. 42 In this regard, studies in human HF have demonstrated that the urinary levels of IL-4 correlate with structural LV remodeling. 43 Also, analogous to the failing heart in our study, the aging rodent heart exhibits a Th2-type phenotype, with augmented IL-4 and IL-13 levels that enhance collagen synthesis and interstitial fibrosis. 44 Hence, Th2 T cells may represent a therapeutic target in chronic ischemic HF to reduce tissue fibrosis and inflammation.
Our assessment of the T-cell network during the development of ischemic HF highlights two additional caveats. Tregs, immunomodulatory T cells that suppress effector T-cell responses, 45 exhibited a biphasic profile in the circulation, initially decreased in frequency early (1 week) after MI (without change in absolute cell counts), with subsequently elevated levels thereafter when compared with sham mice. Although we did not specifically examine the role of Tregs in HF, in light of their potent immunoregulatory features, Treg modulation may represent a viable approach to indirectly modify CD4 + T-cell behavior and chronic inflammation. Moreover, we observed time-dependent alterations in circulating CD4 + T cells and helper T-cell subsets in sham-operated mice, when compared with nonsurgical control mice, which generally approximated normal levels after ≈2 to 4 weeks. Presumably these changes represent a generalized response to thoracotomy and subsequent postoperative healing (and not MI per se) and should be considered in the design of future experimental studies.
HF-Activated CD4 + T Cells Are Both Necessary and Sufficient for Pathological LV Remodeling
Our findings of global CD4 + T-cell activation in murine ischemic HF are consistent with the previous demonstration of increased circulating CD4 + T cells and CD4/CD8 T-cell ratios in human HF. 46, 47 To evaluate the pathophysiological role of T-cell expansion, we first evaluated whether CD4 + T cells are required for LV remodeling. Anti-CD4 antibody administration in established HF halted progressive LV dilatation (without affecting systolic function) and improved chamber hypertrophy, indicating that activated CD4 + T cells are obligatory for the progression of structural disease. Notably, early after acute MI, Hoffman et al 8 have shown that CD4 + T cells are beneficial for infarct wound healing and tissue repair. In contrast, our results show that in chronic ischemic HF, CD4 + T cells impart proinflammatory and detrimental effects on the heart that promote adverse remodeling. Interestingly, antibody-mediated CD3 + T-cell depletion 13 and genetic CD4 + (but not CD8 + ) T-cell disruption 12 in the setting of pressureoverload prevented the long-term development of systolic dysfunction and fibrosis, but did not affect hypertrophy, underscoring important differences about T-cell-mediated remodeling responses in ischemic vis-a-vis nonischemic HF.
Finally, to evaluate whether HF-activated T cells are sufficient to drive tissue remodeling, we defined the effects of adoptive transfer of splenic CD4 + T cells, and cardiac CD3 + T cells, isolated from HF mice. Interestingly, the transfer of HF-activated T-cells recapitulated cardiac injury in naive recipients over an extended follow-up period, with LV systolic dysfunction, chamber or myocyte hypertrophy, and interstitial fibrosis. Moreover, splenocytes exhibited marked upregulation of a broad array of proinflammatory mediators. These results are consistent with our previous work demonstrating a robust tissue-injurious cardiosplenic axis in ischemic HF, 6 and also suggest that heart-localized T cells are responsible for detrimental tissue responses. The cardiac phenotype induced in recipient mice varied depending on splenic CD4 + versus cardiac CD3 + T-cell transfer. As alluded to above, this heterogeneity in response may be related to differences in the overall number of T-cells transferred, as well as disparities in the composition of T-cell subsets within transferred cardiac CD3 + T cells and splenic CD4 + T cells. Nonetheless, despite these limitations, these studies provide important proof-ofconcept for T cells as disease mediators in HF.
The spleen and LNs play several important roles in antigen-specific T-cell immunity, including naive T-lymphocyte recruitment, the screening of antigens, and antigen-loaded DCs in blood and lymph delivered from inflamed sites, the provision of a suitable microenvironment for inducing effector responses T cells in Heart Failure (or antigen-specific tolerance) and homing characteristics, and fostering a niche for memory T cells. 48, 49 The transferability of cardiac-injurious effects of splenic CD4 + T cells from HF mice to naive mice suggests that T cells in HF are activated against cardiac antigens and retain memory for the induction of effector responses on transfer. As both donor and recipient mice carried the CD45.2 allele, our data do not establish whether this is a direct effect of the transferred cells or an indirect effect of secondary activation of immune cells in recipient mice. Also, the nature of the specific antigens responsible for T-cell activation remain undefined and need to be explored in future investigations. Nonetheless, considered together with our previous work, 6 we have established that robust activation of both innate and adaptive immunity, probably in response to as-of-yet poorly defined self-antigens or alarmins released during cardiac injury, are central features and drivers of chronic inflammation in ischemic HF. From a translational stand point, our data suggest that targeting specific immune cell subsets at defined stages of disease may represent a better approach to therapeutic immunomodulation to improve HF.
In summary, chronic ischemic HF in mice is characterized by local and systemic adaptive immune activation of CD4 + and CD8 + T cells, and CD4 + T-cell subsets, including Th1, Th2, Th17, and Treg cells. Failing hearts exhibit Th2 and Th17 cell predominance when compared with Th1 cells and Tregs, respectively, and the spleen exhibits broad expansion of antigen-experienced T cells, including effector and memory T cells. Most importantly, activated CD4 + T cells are obligatory for disease progression in ischemic HF, and sufficiently activated in HF to induce cardiac tissue injury on adoptive transfer. Hence, immunomodulation of CD4 + T cells may represent a novel therapeutic strategy for chronic ischemic HF.
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